Certolizumab pegol in Crohn's disease
1Gastrointestinal Section, Imperial College London, Hammersmith Hospital, London, U.K.
Drugs of Today (Barcelona, Spain : 1998)
|January 31, 2009
Summary
Certolizumab pegol effectively treats immune-mediated inflammatory diseases like Crohn's disease and rheumatoid arthritis by targeting tumor necrosis factor alpha (TNF-alpha). This biologic therapy improves patient quality of life and reduces disease activity and inflammatory markers.
Area of Science:
- Immunology
- Pharmacology
- Gastroenterology
Background:
- Certolizumab pegol is a humanized monoclonal antibody fragment targeting TNF-alpha.
- PEGylation enhances its half-life for subcutaneous administration.
- It is used for immune-mediated inflammatory diseases.
Purpose of the Study:
- To review published data on the efficacy and safety of certolizumab pegol.
- To summarize its use in treating Crohn's disease and rheumatoid arthritis.
- To discuss dosing and adverse events.
Main Methods:
- Review of published clinical trial data.
- Analysis of efficacy in reducing disease activity and inflammatory markers.
- Assessment of safety profile and adverse events.
Main Results:
- Certolizumab pegol improves quality of life and reduces clinical disease activity.
- It leads to decreased levels of C-reactive protein (CRP).
- The safety profile is comparable to other anti-TNF agents, with infections being a major concern.
Conclusions:
- Certolizumab pegol is an effective treatment for immune-mediated inflammatory diseases.
- It offers benefits in disease control and patient well-being.
- Understanding its safety profile is crucial for clinical use.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...